Talazoparib for advanced breast cancer with a DNA repair defect
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is either high-grade ER-positive/HER2-negative, triple-negative, or has a BRCA mutation or a positive HRD test (RECAP)
- Your cancer is locally advanced (cannot be cured) or has spread to other parts of the body (metastatic)
- You have a tumor that can be biopsied (not in the lung or bone)
- You are in reasonably good health (able to care for yourself and do light activity)
- You have had 4 or fewer previous chemotherapy treatments for advanced disease
- You have not had radiation or other cancer drugs within the last 2–4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This trial tests a drug that may help people with advanced breast cancer who have a specific genetic change (in the PALB2 gene). The drug is a PARP inhibitor, which works by targeting cancer cells that have trouble repairing their DNA.
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.